Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;27(4):1860-1862.
doi: 10.1038/s41380-022-01447-4. Epub 2022 Feb 17.

Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al

Guang Chen  1 , Geert Mannens  2 , Marlies De Boeck  3 , Ella J Daly  4 , Carla M Canuso  5 , Greet Teuns  3 , Husseini Manji  6 , Wayne C Drevets  7
Affiliations
Comment

Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al

Guang Chen et al. Mol Psychiatry. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

GC, GM, MDB, EJD, CMC, GT, HM, and WCD are employees of Janssen Research & Development, LLC (the developer of esketamine nasal spray [Spravato®]), Janssen Scientific Affairs, LLC, or Johnson & Johnson, and are stockholders of Johnson & Johnson.

Comment on

References

    1. Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Solís O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021. 10.1038/s41380-021-01093-2. Epub ahead of print. - PMC - PubMed
    1. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharm Rev. 2018;70:621–60. doi: 10.1124/pr.117.015198. - DOI - PMC - PubMed
    1. Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, et al. Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharm Exp Ther. 2016;359:159–70. doi: 10.1124/jpet.116.235838. - DOI - PMC - PubMed
    1. Zarate CA, Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331–8. doi: 10.1016/j.biopsych.2012.03.004. - DOI - PMC - PubMed
    1. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) Mol Psychiatry. 2020;25:1592–603. doi: 10.1038/s41380-018-0256-5. - DOI - PMC - PubMed